Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Sonia Morè"'
Autor:
Francesca Fazio, Maria Teresa Petrucci, Laura Corvatta, Alfonso Piciocchi, Roberta Della Pepa, Paola Tacchetti, Maurizio Musso, Renato Zambello, Angelo Belotti, Sara Bringhen, Elisabetta Antonioli, Concetta Conticello, Nicola Di Renzo, Valerio De Stefano, Pellegrino Musto, Barbara Gamberi, Daniele Derudas, Mario Boccadoro, Massimo Offidani, Sonia Morè
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 485-493 (2024)
Abstract Belantamab mafodotin is the first‐in‐class antibody‐drug conjugates targeting B‐cell maturation antigen to have demonstrated effectiveness in triple‐class refractory multiple myeloma (TCR‐MM) patients. We performed a retrospectiv
Externí odkaz:
https://doaj.org/article/7725cc7a33b84acb8c1ed168063ccd72
Autor:
Alessandra Carella, Francesco Spannella, Sonia Morè, Riccardo Grifoni, Carlo Romano Settanni, Alessandra Mandolesi, Alessandra Filosa, Gaia Goteri, Gianfranco Boccoli, Giammarco Fava
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Solitary primary extraosseous plasmacytoma is a rare disease in the gastrointestinal tract, recently classified as an “exceptional” tumor of the colon site. The real incidence (one case/population/year) is unknown but reasonably less than 1/10,00
Externí odkaz:
https://doaj.org/article/5f34daa6fb8a4c9fb5812e7935097b31
Autor:
Sonia Morè, Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Antonella Poloni, Massimo Offidani
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
Systemic light-chain (AL) amyloidosis is a monoclonal plasma cell disease characterized by the deposition of amyloidogenic monoclonal light-chain fragments in organs, causing their dysfunction. Clinical manifestations could be very aspecific, but the
Externí odkaz:
https://doaj.org/article/0a2fe8a25cf94856aad055d8e0e79489
Autor:
Erika Morsia, Elena Torre, Francesco Martini, Sonia Morè, Antonella Poloni, Attilio Olivieri, Serena Rupoli
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 3, p 1524 (2024)
Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd–Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because co
Externí odkaz:
https://doaj.org/article/bfaa0921bc2f4919a4b8c036b81ec9ff
Autor:
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Publikováno v:
Pharmaceuticals, Vol 16, Iss 11, p 1628 (2023)
In multiple myeloma impressive outcomes have improved with the introduction of new therapeutic approaches, mainly those including naked monoclonal antibodies such as daratumumab and isatuximab. However, moving to earlier lines of therapy with effecti
Externí odkaz:
https://doaj.org/article/db8daf4a1d284442bd1d40543a1ce75f
Autor:
Francesco Saraceni, Sonia Morè
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/113d9ae5468d466aa03e34d927a1db13
Autor:
Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by diffe
Externí odkaz:
https://doaj.org/article/a358ced4010b4db39d23838eb8553e90
Autor:
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Alessandro Fiorentini, Attilio Olivieri, Massimo Offidani
Publikováno v:
Cells, Vol 11, Iss 4, p 606 (2022)
The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for auto
Externí odkaz:
https://doaj.org/article/59b3707f633b4a73a6c85f504cf2589f
Autor:
Sonia Morè, Maria Teresa Petrucci, Laura Corvatta, Francesca Fazio, Massimo Offidani, Attilio Olivieri
Publikováno v:
Pharmaceuticals, Vol 13, Iss 12, p 426 (2020)
Multiple myeloma is a complex hematologic malignancy, and despite a survival improvement related to the growing number of available therapeutic options since 2000s, it remains an incurable disease with most patients experiencing relapse. However, the
Externí odkaz:
https://doaj.org/article/74116f4679a04e92b73d0a0489d45529